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Abstract
Purpose—As the premalignant lesion of human esophageal adenocarcinoma (EAC), Barrett’s
esophagus (BE) is characterized by intestinal metaplasia in the normal esophagus (NE). Gene
expression profiling may help us understand the potential molecular mechanism of human BE.
Methods—We analyzed three microarray datasets (two cDNA arrays and one oligonucleotide
array) and one SAGE dataset with SAM and SAGE(Poisson) to identify individual genes
differentially expressed in BE. GSEA was used to identify a priori defined sets of genes that were
differentially expressed. These gene sets were either grouped according to certain signaling
pathways (GSEA curated), or the presence of consensus binding sequences of known transcription
factors (GSEA motif). Immunohistochemical staining (IHC) was used to validate differential gene
expression.
Results—Both SAM and SAGE(Poisson) identified 68 differentially expressed genes (55 BE
genes and 13 NE genes) with an arbitrary cutoff ratio (≥4 fold). With IHC on matched pairs of NE
and BE tissues from 6 patients, these genes were grouped into 6 categories: Category I (25 genes
only expressed in BE), Category II (5 genes only expressed in NE), Category III (8 genes
expressed more in BE than in NE), and Category IV (2 genes expressed more in NE than in BE).
Differential expression of the remaining genes was not confirmed by IHC either due to false
*Correspondence: Cancer Research Program, Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina
Central University, 700 George Street, Durham, NC 27707. Tel: 919-530-6425; Fax: 919-530-7780; lchen@nccu.edu.
Authors’ contributions JW performed statistical analysis, participated in immunostaining, and drafted the manuscript.
RQ participated in immunostaining and read the slides.
YM carried out the sectioning and participated in immunostaining.
HW instructed the statistical analysis and data interpretation
HP and MT helped with immunostaining
NJS participated in study design, collected the human samples, and participated in data interpretation.
XC designed the study, reviewed the slides, participated in the data interpretation, and drafted the manuscript with JW.
All authors read and approved the final manuscript.
Competing interests The authors declare that they have no competing interests.
NIH Public Access
Author Manuscript
J Gastroenterol. Author manuscript; available in PMC 2013 October 29.
Published in final edited form as:













discovery (Category V), or lack of proper antibodies (Category VI). Besides individual genes, the
TGFβ pathway and several transcription factors (CDX2, HNF1, and HNF4) were identified by
GSEA as enriched pathways and motifs in BE. Apart from 9 target genes known to be up-
regulated in BE, IHC staining confirmed up-regulation of 19 additional CDX1 and CDX2 target
genes in BE.
Conclusion—Our data suggested an important role of CDX1 and CDX2 in the development of
BE. The IHC-confirmed gene list may lead to future studies on the molecular mechanism of BE.
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Introduction
Barrett’s esophagus (BE) is characterized by replacement of normal squamous epithelium
(NE) of the esophagus by intestinalized columnar epithelium, due to chronic
gastroesophageal reflux disease. Patients with BE are at an increased risk of esophageal
adenocarcinoma (EAC), which is now the most rapidly increasing type of cancer in Western
countries (1).
The pathogenesis of intestinal metaplasia (IM) in BE is poorly understood. Stem cells in the
esophageal squamous epithelium or the submucosal glands have been proposed as the
celluar origins of IM (2). Regardless of the site of origin, however, it is generally believed
that inflammatory mediators and/or gastroesophageal refluxate trigger the pluripotent stem
cells to differentiate into intestinalized columnar epithelium. Recent studies have focused on
the potential roles of acid and bile, inflammatory mediators, and intestinal transcription
factors in the pathogenesis of human BE (2-4). Despite these efforts, the mechanism of IM
in BE remains unclear.
The current literature contains 14 studies concerning differential gene expression in NE and
BE (5-18). Several different technologies have been used in these investigations, including
oligonucleotide microarrays (5, 6, 10-13), cDNA microarrays (7-9, 15, 17, 18), serial
analysis of gene expression (SAGE) (16), and proteomics (14). These studies have generated
a wealth of information regarding the differential expression of individual genes.
Knowledge of individual genes involved in the development of BE, however, is inadequate
for mechanistic understanding. Distinct genes do not detect biological processes, and it is
unlikely that the focus on disparate genes will present a cohesive view of the mechanism of
BE. Therefore it is necessary to improve data analysis of gene expression profiles in order to
identify useful links (both individual genes and biological processes) for mechanistic
studies.
Recently, there has been a shift toward pathway-based analysis of microarray data. Gene
Ontology (GO) has been the most popularly used annotation. The GO annotations are vague,
however, and do not provide specific mechanistic information. Furthermore, an individual
gene may be involved in multiple cellular processes. An alternative to GO is gene set
enrichment analysis (GSEA), a computational method that determines whether the
difference in expression of an a priori defined set of genes in two different phenotypes is
statistically significant. This pathway-based approach has proved successful in discovering
molecular pathways involved in human diseases.
The aim of this study was to subject the publicly available gene expression data to the same
set of statistical tools in order to discover differential gene expression patterns in NE and
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BE. The purpose was to discover not only individual genes, but also potential molecular
pathways leading to BE.
Materials and Methods
Gene array datasets
Of the 14 published studies involving gene expression profiling in human BE, six studies
made their raw data publicly available (7-9, 11, 12, 16). Three sets of these raw data were
accessible through the GEO Datasets available on PubMed (GSE2769, GSE1420, and
GSE2444). Others were available from the Stanford MicroArray Database (http://
genomewww5.stanford.edu/), EMBL-EBI (http://www.ebi.ac.uk/aerep/dataselection?
expid=956697506), and the author’s website (http://gastrolab.coi.waw.pl/barrett/). One
dataset was generated using SAGE (16), two using oligonucleotide microarrays (11, 12), and
three using cDNA microarrays (7-9). Various numbers of tissue samples were used in these
six studies:
1. The study by van Baal et al utilized SAGE to analyze tissue samples from 21
patients with non-dysplastic BE. NE and BE tissues were obtained from each
patient with confirmed histology (16). For simplicity, the data generated by this
study was referred to as the “van Baal dataset.”
2. The study by Kimchi et al utilized the U133A Affymetrix GeneChip to analyze 8
matched samples of NE, BE, and EAC. Histological diagnosis was “obtained from
experienced gastrointestinal pathologists” (11). Here, the data from this study was
referred to as the “Kimchi dataset.”
3. The study by Gomes et al analyzed 9 samples of NE, 10 samples of BE, and 5
samples of EAC with an in-house cDNA array consisting of 4,800 sequences (7).
Here, the expression data generated from this study was referred to as the “Gomes
dataset.”
4. The study by Hao et al analyzed 15 samples of NE, 14 samples of BE, and 5
samples of EAC with an in-house cDNA array. NE, BE, and EAC (if present)
tissue samples were obtained from unselected patients. BE and EAC were
confirmed by histopathology. Duplicate microarrays were performed for one of the
samples (677N) (9). Here, the data from this study was referred to as the “Hao
dataset.”
5. The study by Greenawalt et al analyzed 39 samples of NE, 25 samples of BE, and
38 samples of EAC with an in-house cDNA array of 10,500 elements representing
~9,400 unique cDNA clones. Each tissue sample was halved, with one piece
undergoing histopathological review and the other prepared for RNA extraction (8).
Here, the data from this study was referred to as the “Greenawalt dataset.”
6. The study by Ostrowski et al utilized the U133A Affymetrix 2.0 GeneChip to
analyze tissue samples obtained from 29 patients with long-segment BE. Histology
of normal squamous epithelium and BE was histologically confirmed (12). Here,
the data of 23 paired samples were used and was referred to as the “Ostrowski
dataset.”
Initial analysis and exclusion of data
During the initial significance analysis of microarrays (SAM), the Kimchi dataset only had
95 differentially expressed genes of statistical significance at a false discovery rate (FDR) of
1%. Of these, none of the known markers of BE were present. The Gomes dataset had no
genes with statistical significance using SAM analysis. Furthermore, a simple t-test also
Wang et al. Page 3













failed to detect any differential gene expression of statistical significance (p < 0.05).
Therefore, these two datasets were excluded from this study.
Three datasets were then used for analysis: the Hao dataset and the Greenawalt dataset
(cDNA microarrays), and the van Baal dataset (SAGE). For analysis of the Hao dataset,
three BE samples (673, B1, and B6) were eliminated, since Sample 673 exhibited dysplasia,
and Samples B1 and B6 were obtained from BE adjacent to tumor mass. The fourth dataset,
the Ostrowski dataset (oligonucleotide microarray), was used to validate our findings based
on the first three datasets.
Statistical analysis for identification of differentially expressed genes
Our data analysis followed the flowchart presented in Figure 1. In order to determine
individual genes which were differentially expressed between NE and BE, SAM was used to
analyze the original, normalized Hao dataset and Greenawalt dataset (http://www
stat.stanford.edu/~tibs/SAM/) (19). Delta values were adjusted until the FDR was less than
1%. The van Baal dataset was analyzed using a Poisson approach (http://
genome.dfci.harvard.edu/sager/) at a significance level of 0.05 (20). An arbitrary 4-fold cut-
off threshold was then applied to the lists of significant genes from the SAM analysis and
the Poisson-based analysis. Significant genes picked up by at least two of the three datasets
were selected as individual genes differentially expressed between NE and BE. These genes
were designated the SAM/SAGE overlap gene list. Differential expression of some of these
genes was confirmed by immunohistochemical staining (IHC) to create the IHC-confirmed
gene list.
Statistical analysis for identification of differentially expressed gene sets
In order to explore potential involvement of signaling pathways or transcription factors,
GSEA was performed on the Hao dataset and the Greenawalt dataset. GSEA is a
computational method that determines whether a set of genes shows statistically significant
differences between two biological states (http://www.broad.mit.edu/gsea). Two databases
were utilized in our analysis, GSEA motif databases which contain genes that share cis
regulatory motifs that are conserved across the human, mouse, rat, and dog genomes, and
GSEA curated databases which contain genes on certain molecular pathways.
Selected gene sets identified from GSEA were then visualized with Gene Map Annotator
and Pathway Profiler (GenMapp, http://www.genmapp.org) using pathways modified from
the GenMapp database. A GenMapp was constructed to visualize the regulation of
downstream target genes of CDX1 and CDX2 by manually checking the literature.
The individual genes and pathways detected in the Hao and Greenawalt datasets were then
confirmed using the Ostrowski dataset. This dataset was subjected to the same analysis
(SAM, GSEA, and GenMapp), and the results were compared to those obtained from the
analysis of the Hao and Greenawalt datasets.
Human tissue samples
Six matched pairs of tissue samples of NE and BE were obtained from the Department of
Medicine, University of North Carolina at Chapel Hill. These 6 patients were mid-age
Caucasian American men on proton pump inhibitors for various durations. Biopsy tissue
samples of NE and BE were harvested during the first endoscopic examination. None of
these patients had dysplasia or cancer. Clinical diagnosis was confirmed by histopathology.
These samples were used for validation of the SAM/SAGE overlap gene list. Use of human
samples has been approved by the IRB Committee. All human samples were coded with
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patient identifiers removed. Diagnosis of BE was made according to the established criteria
(21).
Immunohistochemical staining
Expression of the SAM/SAGE overlap gene list, diagnostic gene set, and selected target
genes of CDX1 and CDX2 were examined with IHC (Table 1 and Table 2). In brief,
paraffin-embedded tissue sections were deparaffinized, rehydrated, and pretreated by
heating the slides for 5–10 min in 10mM citrate buffer. IHC was performed with the ABC
kit (Vector Labs, Capenteria, CA) according to the manufacturer’s instructions. The sources
of the primary antibodies, catalogue numbers, and working concentrations are listed in Table
1. Normal serum or phosphate buffered saline were used as negative controls, instead of the
primary antibodies. Both positive and negative control slides were processed in parallel.
Alcian blue staining (1% in 3% acetic acid, pH2.5, for 10 min) was performed after IHC on
some slides to visualize cells that produce acidic mucin.
IHC for each gene was scored by one pathologist (RQ) as either positive or negative in the
epithelium of interest. Areas of NE and BE were evaluated separately. In NE, expression in
basal, suprabasal, and superficial cell layers was described separately. In BE, expression in
columnar epithelial cells, goblet cells, and Paneth cells were also described separately.
Localization in the nuclei, cytoplasm, or membrane was indicated.
Results
Individual genes differentially expressed in BE
The result of overlapping the lists of significant genes generated from the cDNA
microarrays (Hao dataset and Greenawalt dataset) and SAGE (Van Baal dataset) studies was
a short list of 68 genes, the SAM/SAGE overlap gene list (Table 1). Output files were
provided in Supplementary File 1. In this list, 55 up-regulated genes in BE were regarded as
BE genes, and 13 down-regulated genes as NE genes.
Differential expression of these 68 genes was examined on six matched pairs of human NE
and BE samples with IHC (Figure 2). Following IHC, the SAM/SAGE overlap gene list was
furthered classified into six categories based on their expression patterns in NE and BE: (1)
Category I: genes expressed in BE only (25 genes); (2) Category II: genes expressed in NE
only (5 genes); (3) Category III: genes expressed at a higher level in BE than NE (8 genes);
(4) Category IV: genes expressed at a higher level in NE than BE (2 genes); (5) Category V:
genes expressed at roughly the same level in NE and BE (6 genes); and (6) Category VI:
genes for which no quality antibodies were available for IHC (22 genes). Since expression
of many genes were examined in a small number of samples, we applied strict criteria when
the IHC staining was interpreted. A higher level of expression referred to increased
expression when all 6 pairs of samples showed the same tendency. Cellular sources and
localization were also characterized and shown in Table 1.
An IHC-confirmed gene list was then generated after exclusion of Category V and Category
VI. This list consisted of 40 genes, 33 BE genes (25 genes of Category I and 8 genes of
Category III) and 7 NE genes (5 genes of Category III and 2 genes of Category IV).
Transcription factors identified by GSEA using motif gene sets
GSEA performed with the motif databases identified several gene sets that contain genes
sharing transcription factor binding sites defined in the TRANSFAC database (version 7.4,
http:///www.gene-regulation.com/). In the Hao dataset, 24 gene sets were enriched for NE
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and 9 for BE (p < 0.05). In the Greenawalt dataset, GSEA detected 1 enriched gene set in
NE and 18 in BE (p < 0.05).
Of the transcription factors identified from these two datasets, CDX2, HNF1, and HNF4 are
known to be critical for gastrointestinal development. Since previous studies had suggested
an important role of CDX1 and CDX2 in intestinal metaplasia in vitro (22, 23), we manually
checked the literature for target genes of CDX1 and CDX2. In total, we found 14 CDX1
target genes and 71 CDX2 target genes (Supplementary Table 1). Most of these target genes
are direct transcriptional targets, and some are genes indirectly regulated and identified by
microarray screening. In addition, there are 22 genes downstream to ATOH1, a CDX2 target
gene and a transcription factor essential for goblet cell development (24).
Using GenMapp, we found that among 71 CDX2 target genes, 31 were up-regulated in BE,
7 were down-regulated and 33 were not significantly changed or not included in the arrays.
Among 14 CDX1 target genes, 6 were up-regulated in BE, 1 was down-regulated and 7 were
not significantly changed or not included (Figure 3A). Since previous studies have clearly
demonstrated overexpression of both CDX1 and CDX2 in BE (25, 26), overexpression of
CDX1 and CDX2 target genes in BE suggested that both CDX1 and CDX2 might play
causative roles in the development of BE.
Seven target genes of CDX1 and CDX2 (FABP1, CDH17, HEPH, TFF3, AGR2, LYZ, and
MUC5AC) were also present in the SAM/SAGE Overlap Gene List and were only tested
once. Two target genes (VIL1 and MUC2) have been examined by us previously (27),
leaving 28 target genes of CDX1 and CDX2 for further examination by IHC. Differential
expression of 19 genes (11 genes of Category I and 8 genes of Category III) was confirmed
(Table 2; Figure 4). We failed to detect 6 genes with IHC (CA1, CLU, HOXA9, MMP7,
TM4SF4, and UGT2B7) due to lack of proper antibodies. GFI1, HOXA10, and NR0B2
were found to be more highly expressed in NE than BE (data not shown).
Molecular pathways identified by GSEA using curated gene sets
GSEA was also performed using the curated databases to discover molecular pathways
involved in the development of BE (Supplementary File 1). At asignificance level of 0.05,
GSEA detected 48 enriched gene sets in NE and 43 enriched gene sets in BE using the Hao
dataset. GSEA also detected 6 enriched gene sets in NE and 81 enriched gene sets in BE
using the Greenawalt dataset.
Among these pathways, the TGFβ pathway was identified as an activated pathway in BE in
both datasets. The expression pattern of BMP/TGFβ pathway genes was visualized using
GenMapp (Figure 3B). Consistent with the recent findings that BMP4 induced metaplastic
changes in esophageal cells in vitro (28), the widespread up-regulation of BMP/TGFβ target
genes in BE suggested an important role of BMP/TGFβ signaling pathway in the
development of BE.
Confirmation of above findings using oligonucleotide microarray data (the Ostrowski
dataset)
In order to confirm the above results using data obtained from a different array platform, we
also analyzed the Ostrowski dataset for differential gene expression with SAM and GSEA.
Of the 68 genes in the above-mentioned SAM/SAGE overlap gene list, 57 were also found
to be significantly up-regulated or down-regulated in BE. Of the remaining 11 genes which
were not detected in the Ostrowski dataset (BCMP11, FOXA3, GDDR, ITLN1, KCNE3,
OCIAD2, ORF1-FL49, REG4, TM4SF8, GJB2, and MALAT1), none were originally
included in the U133A Affymetrix 2.0 gene chip used by Ostrowski et al.
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GSEA performed on the Ostrowski dataset using the motif database detected 4 gene sets in
NE and 99 gene sets in BE (p<0.05). CDX2, HNF1, and HNF4 were among the significant
gene sets of BE. Besides these, GSEA also identified SOX9, TTF1, and GATA6 as enriched
gene sets in BE.
Using the curated database, GSEA detected 15 gene sets in NE samples and 292 gene sets in
BE (p<0.05). The TGFβ signaling pathway was among the enriched gene sets of BE. This
was consistent with the discovery by Ostrowski et al. (12).
GenMapp showed that many target genes of CDX1 and CDX2 and the BMP/TGFβ signaling
pathway were up-regulated in BE (Supplementary Figure 1A, B). This was consistent with
the above results in Figure 3 using the data from cDNA microarrays.
Discussion
In this study, we identified 40 genes differentially expressed in NE and BE, which were
validated by IHC staining. Our data also suggested that multiple genetic pathways (e.g.,
BMP/TGFβ pathway) and transcription factors (e.g., CDX1, CDX2) might participate in the
development of BE. This observation is consistent with a well-accepted theory that
transdifferentiation or metaplasia is mediated by activation or inactivation of transcription
factors, which further regulate their target genes specific for certain cellular functions (29).
Among the 40 genes differentially expressed in NE and BE, there were 33 genes expressed
only in BE (Category I, 25 genes) or expressed in BE more than in NE (Category III, 9
genes). Some of these genes (e.g., AGR2, ANXA10, CLDN18, KRT8, MUC3B, MUC5AC,
TACSTD1/EpCAM, TFF1, TFF2, TFF3, TSPAN1) have already been reported to be up-
regulated in human BE (14, 16, 30-37). Some genes are known differentiation markers of
certain cell lineages in BE. For example, LYZ is a known marker of Paneth cells, KRT8 a
marker of columnar epithelial cells, and TFF3 a marker of goblet cells. None of the markers
of enteroendocrine cells appeared in our gene list. It was probably due to a small population
of such cells in BE. Many genes (e.g., CDH17, CTSE, FABP1, FOXA3, HEPH, IQGAP2,
ITLN1, LGALS2, LIPF, MEP1A, MYO1A, PIGR, SELENBP1) are known to be highly
expressed in the stomach and/or the intestine. Function-wise, some genes (e.g., CA2,
CLDN18) were up-regulated in BE as a defensive mechanism against reflux (32, 38).
Besides these 40 genes whose differential expression was validated by IHC, seven genes of
Category VI (BCMP11, GDDR, GKN1, ITLN1, MUC13, REG4, TM4SF4) were very likely
to increase in BE versus NE because of their expression patterns in the gastrointestinal
epithelium and gastric IM. As a TFF2-binding protein, GDDR was shown to be up-regulated
in human BE (Dr. William Otto, Cancer Research UK, London, UK; personal
communication). These data clearly showed that BE is a phenotype of multi-directional
differentiation, suggesting columnar differentiation during the development of BE.
Seven genes were expressed only in NE (Category II, 5 genes) or expressed more in NE than
in BE (Category IV, 2 genes). These 7 genes are known to be expressed in stratified
squamous epithelium, including the esophagus (39-45). Some of these genes were found to
be down-regulated in esophageal squamous cell carcinoma, and associated with clinical
prognosis (39, 42, 43, 45). Down-regulation of these squamous marker genes suggested
squamous dedifferentiation in BE. These data were consistent with our previous study
showing loss of squamous markers and gain of columnar markers as two facets of BE (27).
Several transcription factors were identified by GSEA as potential players in BE, including
CDX2, HNF1, HNF4, SOX9, TTF1, and GATA6. Among these factors, Sox9 is required for
differentiation of Paneth cells (46). TTF1 regulates expression of CLDN18, one of the BE
genes identified in this study (Table 1; Figure 2IC) (47). GATA6 has been identified as a
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gene differentially expressed in human BE (48). However, CDX2 might be a pivotal switch
between intestinal columnar epithelium and squamous epithelium in the gastrointestinal
tract.
In normal intestinal epithelium, CDX2 and CDX1 are expressed in most cell lineages with
Paneth cells having a lower level of expression than other cells. Squamous epithelial cells of
normal human esophagus do not express CDX2 or CDX1, while submucosal glands weakly
express CDX2 in the cytoplasm. In human BE, CDX2 is expressed in both goblet and non-
goblet cells. Dysplasia and EAC may have decreased levels of or even absence of expression
of CDX2 and CDX1. In EAC, a high level of CDX2 expression was usually associated with
well or moderately differentiated tumors. A low level of CDX2 mRNA was detectable by
RT-PCR in biopsy samples of squamous epithelium of GERD patients, even before the
appearance of CDX2 protein and other marker genes of intestinal metaplasia and
histological metaplasia. CDX2 expression also precedes CDX1 expression. Many “marker”
genes of BE, such as VIL, GCC, SI, MUC2, TFF3, FABP1, are known to be regulated by
CDX2 and/or CDX1 at the transcriptional level. Treatment of human and rodent esophageal
squamous epithelial cells with either acid or bile acids, which mimics gastroesophageal
reflux, induced expression of CDX2. Transfection of CDX2 into human esophageal
squamous epithelial cells induced metaplastic changes in morphology and gene expression.
CDX2 regulates expression of critical genes of goblet cell differentiation, such as ATOH1,
KLF4, MUC2, MUC4, RETNLB and TFF3 (22). It should be noted that the presence of
goblet cells is diagnostic of BE.
We manually picked up 14 target genes of CDX1 and 71 target genes of CDX2 from the
literature (Figure 4A). Using IHC, differential expression of 19 genes (11 genes of Category
I and 8 genes of Category III) was confirmed (Table 2; Figure 5). In addition, 9 target genes
of CDX1 and CDX2 (VIL, MUC2, FABP1, CDH17, HEPH, TFF3, AGR2, LYZ, and
MUC5AC) have been described above (Table 1 and Figure 2) or previously by us (27).
These data highly suggested a causative role of CDX1 and CDX2 in the development of
human BE.
GSEA analysis identified TGFβ pathway as one of the signaling pathways activated in BE
(Figure 4B). This is consistent with a recent study showing increased expression of BMP4
and activation of its signaling pathway in BE. Treatment of primary squamous cells with
BMP4 induced squamous dedifferentiation and columnar differentiation (4, 28). Recently,
CDX2 was found to interact with SMAD3 independent of SMAD4, resulting in stimulation
of SMAD3 transcriptional activity. CDX1 also interacted with SMAD3 by inhibiting
SMAD3/SMAD4-dependent transcription (49). Treatment of human gastric cancer cells
with BMP2 and BMP4 induced expression of CDX2, as well as that of MUC2 and LI-
Cadherin (50). These data suggested that multiple pathways and factors might interact with
each other in driving the development of BE. However, caution should be excised when
GSEA data are interpreted. Functional analysis in vivo will determine whether and how
these signaling pathways and transcription factors may participate in the development of BE.
In summary, we identified and validated genes differentially expressed in human BE.
CDX1/CDX2 and the BMP/TGFβ signaling pathway may participate in the development of
BE. Further studies may be warranted to determine how these differentially expressed genes
are regulated in BE, and how these signaling pathways (e.g., BMP/TGFβ pathway) and
transcription factors (e.g., CDX1, CDX2) may interact with each other to mediate the
development of BE.
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The overall design of this study. The right branch represented the process of generating a list
of individual genes differentially expressed in NE and BE, while the left branch indicated
the methodology of pathway analysis. IHC was used to validate differential gene expression
in NE and BE.
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Confirmation of differential gene expression in human BE by IHC. Expression of four
categories of genes are shown here: (1) Category I: genes expressed in BE only (25 genes);
(2) Category II: genes expressed in NE only (5 genes); (3) Category III: genes expressed
higher in BE than NE (8 genes); (4) Category IV: genes expressed higher in NE than BE (2
genes). Due to the space limitations, staining of the NE slides for Category III genes were
not shown. Scale bar = 50μm.
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Visualization of target genes of CDX1 and CDX2, and the BMP/TGFβ signaling pathway
with GenMapp, using cDNA array data (the Hao dataset and the Greenawalt dataset). Red
boxes indicated genes that were up-regulated in BE, while green boxes indicated genes that
were down-regulated in BE. Uncolored boxes denoted genes that were not found to be
differentially expressed or were not present in the dataset. Dashed boxes represented genes
that had multiple spots on the microarray showing differential expression. The central color
of dashed boxes with multiple colors denoted the expression pattern for the mode of spots,
while the rim color denoted the expression pattern of the minority of spots. Figure 4A
showed differential expression of target genes of CDX1 and CDX2. Figure 4B showed
differential expression of genes of the BMP/TGFβ signaling pathway.
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IHC staining of BE tissue for selected target genes of CDX1 and CDX2. Differential
expression of 19 genes (11 genes of Category I and 8 genes of Category III) were validated.
Scale bar = 50μm.
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